HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.